Citation Impact
Citing Papers
Here, There Be Dragons : Charting Autophagy-Related Alterations in Human Tumors
2012
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
CD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
2012
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
2008
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
2015 Standout
Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice
2011
BRCAness revisited
2016
Ovarian cancer
2014 Standout
Wnt signaling in cancer
2016 Standout
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012
Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community
2012
Nomograms in oncology: more than meets the eye
2015 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Linker Technologies for Antibody–Drug Conjugates
2013
Efficiency in Nonenzymatic Kinetic Resolution
2005
Highly Enantioselective Synthesis of 3‐Substituted Furanones by Palladium‐Catalyzed Kinetic Resolution of Unsymmetrical Allyl Acetates
2012 StandoutNobel
Epidemiology of Prostate Cancer
2019 Standout
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
2014
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Colorectal cancer
2013 Standout
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Targeted therapies in bladder cancer: an overview of in vivo research
2015
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
2010
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
Molecular mechanisms of cisplatin resistance
2011 Standout
Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
2017
Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer
2011
First- and Second-Line Therapy for Metastatic Urothelial Carcinoma of the Bladder
2011
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Isotope-targeted glycoproteomics (IsoTaG) analysis of sialylated N- and O-glycopeptides on an Orbitrap Fusion Tribrid using azido and alkynyl sugars
2016 StandoutNobel
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
2016 Standout
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers
2012
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer
2013
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
2013
Urothelial carcinoma management in elderly or unfit patients
2016
Cascade Reactions in Total Synthesis
2006 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Maximizing Cure for Muscle-Invasive Bladder Cancer: Integration of Surgery and Chemotherapy
2011
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
2013
Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
2014
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
2011
The PI3K Pathway in Human Disease
2017 Standout
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012
Clinical applications of the CellSearch platform in cancer patients
2018
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy
2010
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function
2012
Molecular biology and targeted therapies for urothelial carcinoma
2015
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Detection of Asymptomatic Recurrence During Routine Oncological Followup After Radical Cystectomy is Associated With Improved Patient Survival
2011
The Activation of Carboxylic Acids via Self-Assembly Asymmetric Organocatalysis: A Combined Experimental and Computational Investigation
2016 StandoutNobel
Resolution of Diols via Catalytic Asymmetric Acetalization
2015 StandoutNobel
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Hereditary gynaecological malignancies: advances in screening and treatment
2012
Effizienz in der nichtenzymatischen kinetischen Racematspaltung
2005
Bladder Cancer
2020 Standout
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible
2019
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
2010
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Kinetic Resolution of Homoaldols via Catalytic Asymmetric Transacetalization
2010 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Prospective comparison of quality‐of‐life outcomes between ileal conduit urinary diversion and orthotopic neobladder reconstruction after radical cystectomy: a statistical model
2013
Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC–MS/MS
2015
Enantioselective liquid–liquid extraction of (R,S)-phenylglycinol using a bisnaphthyl phosphoric acid derivative as chiral extractant
2010 StandoutNobel
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Complete Field Guide to Asymmetric BINOL-Phosphate Derived Brønsted Acid and Metal Catalysis: History and Classification by Mode of Activation; Brønsted Acidity, Hydrogen Bonding, Ion Pairing, and Metal Phosphates
2014 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens
2018 Standout
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
2011
Second-Line Systemic Therapy for Metastatic Urothelial Carcinoma of the Bladder
2013
Works of David Gallagher being referenced
Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting
2008
Detection of circulating tumor cells in patients with urothelial cancer
2008
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
2010
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
2013
Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
2010
Bladder Cancer
2009
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
2010
Synthesis of highly potent second-generation taxoids through effective kinetic resolution coupling of racemic ?-lactams with baccatins
2000
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
2013
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
2010
Susceptibility Loci Associated with Prostate Cancer Progression and Mortality
2010
Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
2007
GermlineBRCAMutations Denote a Clinicopathologic Subset of Prostate Cancer
2010
Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
2011
Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
2008